|
|
 Previous Article | Table of Contents | Next Article 
A randomized controlled trial of pentoxifylline for the prevention of
regimen-related toxicities in patients undergoing allogeneic marrow
transplantation
RA Clift, JA Bianco, FR Appelbaum, CD Buckner, JW Singer, L Bakke, WI Bensinger, RA Bowden, GB McDonald and M Schubert
Fred Hutchinson Cancer Research Center, Seattle, WA 98104-2092.
This study evaluated the effect of pentoxifylline (PTX) on the incidence of
regimen-related toxicity in patients receiving allogeneic marrow
transplants from related donors. All patients received a regimen of
methotrexate and cyclosporine as prophylaxis against acute graft-
versus-host disease (GVHD). Patients were randomized to receive PTX or a
placebo for 70 days and the outcome was examined in a blinded fashion.
Forty-four patients were evaluate in each study arm. PTX had no significant
effect on engraftment, the incidence of GVHD, venocclusive disease of the
liver, infection, the need for oxygen, posttransplant survival, or the
duration of hospitalization. Patients receiving PTX were significantly more
likely to develop major elevations of serum creatinine levels. PTX was
poorly tolerated and induced significantly more vomiting than the placebo.
PTX as administered in this randomized study was associated with
significant toxicity and offered no benefit in reducing transplant-related
morbidity or mortality.
Volume 82,
Issue 7,
pp. 2025-2030,
10/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Diaconescu, C. R. Flowers, B. Storer, M. L. Sorror, M. B. Maris, D. G. Maloney, B. M. Sandmaier, and R. Storb
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
Blood,
September 1, 2004;
104(5):
1550 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Okunieff, E. Augustine, J. E. Hicks, T. L. Cornelison, R. M. Altemus, B. G. Naydich, I. Ding, A. K. Huser, E. H. Abraham, J. J. Smith, et al.
Pentoxifylline in the Treatment of Radiation-Induced Fibrosis
J. Clin. Oncol.,
June 1, 2004;
22(11):
2207 - 2213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, L. D. DeLeve, P. S. Kamath, and A. Tefferi
Hepatic Veno-occlusive Disease (Sinusoidal Obstruction Syndrome) After Hematopoietic Stem Cell Transplantation
Mayo Clin. Proc.,
May 1, 2003;
78(5):
589 - 598.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. A. Tabbara, K. Zimmerman, C. Morgan, and Z. Nahleh
Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results
Arch Intern Med,
July 22, 2002;
162(14):
1558 - 1566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Kostler, M. Hejna, C. Wenzel, and C. C. Zielinski
Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment
CA Cancer J Clin,
September 1, 2001;
51(5):
290 - 315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Stuber, A Buschenfeld, A von Freier, T Arendt, and U R Folsch
Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy
Gut,
August 1, 1999;
45(2):
229 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Bright, C. Du, M. Coon, S. Sriram, and S. J. Klaus
Prevention of Experimental Allergic Encephalomyelitis via Inhibition of IL-12 Signaling and IL-12-Mediated Th1 Differentiation: An Effect of the Novel Anti-Inflammatory Drug Lisofylline
J. Immunol.,
December 15, 1998;
161(12):
7015 - 7022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
